ICYMI - New FDA Guidance Document: Individualized Human Genome Editing Products: Considerations for BLA Submission and Postapproval Management
https://t.co/yshLvrgpNb
The 2026 Breakthroughs abstracts are now live!
Get a preview of the latest research and scientific advancements being presented at #ASGCTBreakthroughs, happening Nov. 12-13 in Nashville and virtually.
There's still time to register and join experts from across the cell and gene therapy field as they share emerging research, innovative approaches and new developments shaping the future of CGT.
Explore the abstracts and register today: https://t.co/9v2kGJvBru
A powerful gene-editing technique has been used to edit DNA directly in a person’s body — the first known instance of such a treatment.
https://t.co/FmRWT0LGRu
In this review, researchers summarize some current strategies to scale-up the production of nanomedicines for translational investigations.
https://t.co/gLxOPfaRcc
Hot off the press! 📢 Our Q3 2026 Gene, Cell and RNA Therapy Landscape Report, developed with Citeline, is here.
Explore seven new approvals, an expanding clinical pipeline and the latest advancements shaping the field.
Read more: https://t.co/kUwiaoqENv
#ASGCT#CGT
We're back with another SCGE Spotlight! This month, we've got:
- 2 recent publications
- Links to our "Meet the Expert" webinar series recordings
- Upcoming SCGE researcher presentations at ASGCT Breakthroughs
https://t.co/LuBhE3yZZn
On September 29th, the SCGE hosted a public workshop titled “Rethinking Clinical Delivery, Regulation, and Payment Models for Individualized Platform-Based Genome Editing Therapies”.
The recording for this workshop is available now at: https://t.co/CoEVCqUaEh
On September 29th, the SCGE hosted a public workshop titled “Rethinking Clinical Delivery, Regulation, and Payment Models for Individualized Platform-Based Genome Editing Therapies”.
The recording for this workshop is available now at: https://t.co/CoEVCqUaEh
New piece in @CGT_Insights on scaling individualized CRISPR therapeutics:
The technical challenge: conventional biomanufacturing optimizes for volume, but individualized gene therapy requires treating each patient as their own 'batch.' @somaticediting
10.18609/cgti.2026.087
Here, a team including SCGE researchers have developed a cost-effective mass-production method for manufacturing vascularized kidney organoids, which has improved production efficiency by more than 50 times compared to conventional culture systems.
https://t.co/tS26X6UZXC
As AI and biotech converge and reach deeper into our lives, critical questions around the technology's purpose and trajectory emerge. Join us for "Engineering Health for the Common Good" @UWMadison!️ FREE, open to the public: https://t.co/auIy4H8cMt
#Bioethics#CRISPR#AI
Here, SCGE researchers discuss their idea for the use of a customizable prime editing platform in an "umbrella-of-umbrellas" clinical trial including subjects with any of seven urea cycle disorders. #PublicationFriday
https://t.co/w6c7Rm8mOF